Ascendis Pharma A (ASND) Total Non-Current Liabilities (2019 - 2026)

Ascendis Pharma A has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $454.9 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $454.9 million, up 18.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $454.9 million (up 18.24% YoY), and the FY2025 annual result was $461.0 million, up 18.16% from the prior year.
• Total Non-Current Liabilities came in at $454.9 million for Q1 2026 at Ascendis Pharma A, down from $461.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $798.9 million in Q3 2023 to a low of $249.5 million in Q2 2024.
• The 5-year median for Total Non-Current Liabilities is $454.9 million (2026), against an average of $492.4 million.
• Across the five-year window, Total Non-Current Liabilities soared 532.72% in 2022 and tumbled 62.21% in 2023, its largest moves.
• Ascendis Pharma A's Total Non-Current Liabilities stood at $668.4 million in 2022, then plunged by 62.21% to $252.6 million in 2023, then jumped by 54.44% to $390.1 million in 2024, then advanced by 18.16% to $461.0 million in 2025, then dropped by 1.32% to $454.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $454.9 million (Q1 2026), $461.0 million (Q4 2025), and $400.2 million (Q3 2025), per Business Quant data.